Eisai Co., Ltd. (“the Company”) and its affiliates (collectively referred to as “the Group”)
List of Group Companies(As of March 31, 2024)
Company Name

Location

Share Capital

Description ofOperations (*1)

VotingRights(*2)

Relationship

Note(Consolidated Subsidiaries)
Unit=million
The Company
commissions
pharmaceutical R&D
The Company
commissions a part ofmanagement and otherfunctions related to R&D
The Company purchases
business support services,etc.
The Company
commissions
pharmaceutical R&D andproduction / purchases
pharmaceutical products
The Company
commissions systemdevelopment

KAN ResearchInstitute, Inc.

Kobe, Japan70JPY

Pharmaceutical R&D

100.00%Eisai R&D
Management Co.,Ltd.

Tokyo, Japan

16

JPY

Management ofpharmaceutical R&D

100.00%Sunplanet Co., Ltd.

Tokyo, Japan

455

JPY

Business supportservices, etc.

100.00%EA Pharma Co.,Ltd.

Tokyo, Japan

9,145

JPY

Pharmaceutical R&D/ production / sales

60.00%

Arteryex Inc.

Tokyo, Japan

434

JPY

Software planningand development

64.42%

Theoria
technologies Co.,Ltd.

Tokyo, Japan

350

JPY

Other services

100.00%-*6

Eisai Corporation ofNorth America

New Jersey,
USA

Americas holding
company

100.00%

-*3

*7

*3

Unit=thousand

Eisai Inc.

New Jersey,
USA

Eisai Innovation,
Inc.

1,766,700

USD

The Company
commissions
pharmaceutical R&D andproduction / sells
pharmaceutical products
and APIThe Company
commissions managementof investment in the U.S.
and Europe

151,600

USD

Pharmaceutical R&D/ production / sales

100.00%(100.00%)

Massachusetts,
USA

1

USD

Management ofpharmaceuticalinvestment

100.00%(100.00%)

Eisai Ltd.

Ontario, Canada

30,000CAD

Pharmaceutical sales

100.00%(100.00%)-

Eisai China
Holdings Ltd.

Jiangsu, China

664,465

RMB

Chineseheadquarters /holding company

100.00%(100.00%)-Eisai China Inc.

Jiangsu, China

576,125

RMB

Pharmaceuticalproduction / sales

100.00%(100.00%)

Jiangsu, China

70,000

RMB

Pharmaceutical sales

100.00%(100.00%)

Liaoning, China

50,000

RMB

Pharmaceuticalproduction / sales

100.00%(100.00%)

Eisai Europe Ltd.

Hertfordshire,UK

184,138

GBP

Europe headquarters/ holding company,
pharmaceutical sales

100.00%Eisai Ltd.

Hertfordshire,UK

46,009GBP

Pharmaceutical R&D/ sales100.00%(100.00%)

Eisai Manufacturing
Ltd.

Hertfordshire,UK

38,807

GBP

Pharmaceutical R&D/ production

100.00%(100.00%)

Eisai GmbH

Frankfurt,
Germany

7,669

EUR

Pharmaceutical sales

100.00%(100.00%)

Eisai (Suzhou)
Trading Co., Ltd.
Eisai (Liaoning)
PharmaceuticalCo., Ltd.

The Company sells
pharmaceutical products
and APIThe Company sells
pharmaceutical products*3*5*3*3*3

The Company
commissions management
and administration ofpharmaceutical business
The Company
commissions
pharmaceutical R&D
The Company sells
pharmaceutical products
and API / is commissioned
pharmaceutical R&D-*3*3*3

Company Name

Location

Share Capital

Description ofOperations (*1)

VotingRights(*2)

Relationship

Note

Unit=thousand
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)

Eisai S.A.S.

Paris, France

19,500EUR

Pharmaceutical sales

Eisai B.V.

Amsterdam,
Netherlands

540

EUR

Pharmaceutical sales

Eisai Farmacéutica
S.A.

Madrid, Spain

4,000

EUR

Pharmaceutical sales

Eisai S.r.l.

Milan, Italy

3,500

EUR

Pharmaceutical sales

3,000

CHF

Pharmaceutical sales

10,000SEK

Pharmaceutical sales

1,250

EUR

Pharmaceutical sales

2,001

EUR

Pharmaceutical sales

Vienna, Austria

2,000

EUR

Pharmaceutical sales

Moscow, Russia

4,000

RUB

Pharmaceutical sales

Singapore34,469

SGD

Asia holding
company

100.00%

The Company sells
pharmaceutical products
The Company
commissions
pharmaceutical R&D
The Company sells
pharmaceutical products
The Company sells
pharmaceutical products
The Company sells
pharmaceutical products
and APIThe Company sells
pharmaceutical products
The Company sells
pharmaceutical products
The Company sells
pharmaceutical products
The Company sells
pharmaceutical products
The Company
commissions
pharmaceutical R&D andproduction / sells
pharmaceutical products
and API / purchases
pharmaceutical products
and API

Eisai Pharma AG
Eisai AB
Eisai Farmacêutica,
Unipessoal Lda.
Eisai SA/NV
Eisai GesmbH
Limited LiabilityCompany Eisai
Eisai Asia Regional
Services Pte. Ltd.
Eisai (Singapore)
Pte. Ltd.
Eisai ClinicalResearchSingapore Pte. Ltd.

Zurich,Switzerland
Stockholm,
SwedenLisbon,Portugal
Brussels,
Belgium

Singapore

300

SGD

Pharmaceutical sales

100.00%(100.00%)

Singapore

10

SGD

Pharmaceutical R&D

100.00%(100.00%)-Eisai Taiwan Inc.

Taipei, Taiwan

270,000

TWD

Pharmaceutical sales

100.00%Eisai (Thailand)Marketing Co., Ltd.

Bangkok,Thailand

103,000

THB

Pharmaceutical sales

100.00%(100.00%)

PT Eisai Indonesia

Jakarta,Indonesia

1,630,000

IDR

Pharmaceuticalproduction / sales100.00%

470

MYR

Pharmaceutical sales

140,000

PHP

Pharmaceutical sales

Hong Kong

500

HKD

Pharmaceutical sales

Eisai Korea Inc.

Seoul,South Korea

3,512,000

KRW

Pharmaceutical sales

100.00%

Eisai
Pharmaceuticals
India Pvt. Ltd.

AndhraPradesh,India

2,708,324

INR

Pharmaceutical R&D/ production / sales

100.00%(11.08%)Eisai Australia Pty.
Ltd.
Eisai Laboratórios
Ltda.
Eisai Laboratorios
S. de R.L. de C.V.
Eisai New ZealandLtd.
Eisai Vietnam Co.,Ltd.

Sydney,Australia
São Paulo,
BrazilMexico City,
MexicoAuckland,
New ZealandHo Chi Minh,
Viet Nam

4,000

AUD

Pharmaceutical sales

100.00%87,899BRL

Pharmaceutical sales

3MXN

Pharmaceutical sales

2,050

NZD

Pharmaceutical sales

20,781,000

VND

Pharmaceutical sales

100.00%-Eisai Israel Ltd.

Tel Aviv, Israel

5,000

ILS

Pharmaceutical sales

100.00%(100.00%)-Johannesburg,
South Africa

36,500ZAR

Pharmaceuticalbusiness100.00%

The Company sells
pharmaceutical products

Eisai (Malaysia)
Sdn. Bhd.
HI-Eisai
Pharmaceutical Inc.
Eisai (Hong Kong)
Co., Ltd.

Eisai
Pharmaceuticals
Africa (Pty) Ltd
Other – 2companies

Petaling Jaya,MalaysiaManila,
Philippines----

100.00%(5.74%)
50.00%(1.45%)
100.00%(10.00%)100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)

---

*4

*3

Company Name

Location

Description ofOperations (*1)

Share Capital

VotingRights(*2)

Relationship

Note(Associated Companies Accounted for Using the Equity Method)
Unit=million
Unlimit Health
LimitedShanghai, China

30

RMB

Provision of medicalservices

49.00%(49.00%)-Notes:*1. "Description of Operations" indicates the segment applicable to the respective entity.
*2. Voting rights (%): Figures in parentheses show percentage indirectly owned by the Company.
*3. Significant subsidiaries.
*4. HI-Eisai Pharmaceutical Inc. is considered to be a consolidated subsidiary as the Company holds effective control
over its operation even though the Company's voting rights do not exceed 50%.
*5. Eisai Inc. is the only subsidiary whose revenue to external customers exceeds 10% of consolidated revenue reported
in the consolidated financial statements for the fiscal year ended March 31, 2024. Key financial results (in Japaneseyen) of Eisai Inc. are as follows:
Revenue
Operating Profit
Profit for the yearTotal Equity
Total Assets
*6.
*7.
*8.

¥359,733 mil.
¥(15,976) mil.
¥(12,882) mil.
¥360,754 mil.
¥529,063 mil.

In September 2023, the Company established Theoria technologies Co., Ltd.
In April 2024, the Company absorbed and merged with KAN Research Institute, Inc.
In April 2024, Eisai Europe Ltd. established Eisai Pharmaceuticals Single Person Limited Liability Company (in SaudiArabia).